Sector in which the organization works:
Short description of the organization and its work to control and eliminate NTDs
Trachoma is an infection of the eye cause by the bacterium Chlamydia trachomatis, and affects roughly 40 million people across 53 countries.
Pfizer is working to help end the suffering and the cycle of poverty caused by this debilitating disease by partnering with the WHO's Alliance for the Global Elimination of Blinding Trachoma (GET2020) and the International Trachoma Initiative.
In 1998, Pfizer and the Edna McConnell Clark Foundation co-established the International Trachoma Initiative (ITI), an independent not-for-profit organization dedicated to the elimination of blinding trachoma. ITI, housed at The Task Force for Global Health, manages Pfizer's global donation of the antibiotic Zithromax® for the elimination of blinding trachoma and collaborates with governmental and nongovernmental agencies at the local, national and international levels to implement the SAFE strategy (Surgery, Antibiotics, Facial cleanliness, Environmental improvement).
Pfizer is committed to providing Zithromax® in the effort to help eliminate blinding trachoma by 2020 and preserve and restore the health and well-being of affected families worldwide. To date, Pfizer has donated more than 340 million Zithromax® treatments in 28 countries with plans to soon be active in many more.
New funding since the London NTD declaration has led to innovative projects and increased momentum in the trachoma community. First, in the biggest disease mapping initiative in public health history, more than 1 million people have been examined for signs of trachoma in nearly 1,000 districts in the last 14 months, thanks to the Global Trachoma Mapping Project (GTMP), funded by the British government. The mapping consortium is working with 18 implementing organizations to conduct trachoma surveys in more than 30 countries. Trained health workers use smart phones to upload prevalence data, which is analyzed and shared online so targeted interventions can begin faster. The project continues through March 2015, and will result in a more complete understanding of trachoma prevalence worldwide, which will allow targeted treatment interventions to begin.
New funds from The Queen Elizabeth Diamond Jubilee Trust are going through the International Coalition for Trachoma Control (ICTC) to fast-track progress in five Commonwealth countries to eliminate blinding trachoma by 2020.
Pfizer, Inc. is one of the 20 original endorsers of the London Declaration
International Trachoma Initiative